Remdesivir for Respiratory Syncytial Virus Infection

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen ByJoshua Hill, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Fred Hutchinson Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.

Eligibility Criteria

This trial is for immunocompromised individuals with an upper respiratory tract infection due to RSV. It's specifically aimed at patients undergoing cellular or bispecific antibody therapy, which can include those with conditions like multiple myeloma or lymphoma.

Inclusion Criteria

I am 18 years old or older.

My oxygen levels are 92% or higher without extra oxygen.

Exclusion Criteria

I need extra oxygen due to my illness or my oxygen levels are below 92%.

I have new lung issues on X-rays due to RSV.

I am currently receiving or have received experimental treatment for my RSV infection.

I haven't had serious lung infections in the last 2 weeks or they've been treated.

Participant Groups

The study is testing the effectiveness of remdesivir in treating RSV infections in the upper respiratory tract among immunocompromised patients. Participants will undergo biospecimen collection, nasal swabs, and survey administration as part of the phase II trial process.

1Treatment groups

Experimental Treatment

Group I: Treatment (remdesivir)Experimental Treatment4 Interventions

Patients receive remdesivir IV over 30-120 minutes on days 1-5, with the option to extend to day 10 at the investigator's discretion, in the absence of disease progression or unacceptable toxicity. Patients also undergo nasal swabs and blood sample collection throughout the study.